Iovance Biotherapeutics

This #FourthOfJuly, celebrate freedom—and protect your skin. ☀️ About 9 in 10 skin cancers are linked to UV. Wear SPF 30+, cover up, seek shade, and skip the tanning beds. Learn more from the @MelanomaReAlli #SunSafety #MelanomaAwareness

In sarcoma, awareness and early detection go hand in hand and every share helps. Spread the word about this rare cancer and help someone catch it sooner. #SarcomaAwarenessMonth

For BRAF-mutated melanoma, timing matters. Dr. Sajeve Thomas on why earlier planning may reshape the treatment journey. Read more ⬇️ #Melanoma #TILTherapy #Oncology tinyurl.com/bdcuy8yw

Pride isn't just a month. It's a mindset. At Iovance, we're rewriting what's possible for cancer patients — and that takes bold thinking, diverse lived experiences, and an inclusive culture. To our LGBTQ+ community and allies: you make us stronger.🌈#PrideMonth #CellTherapy

What if your own immune system could fight cancer? @fox5dc shares how #TILTherapy offered here at MedStar Georgetown is giving new hope to patients with advanced #melanoma. Watch their conversation here. ms.spr.ly/6015vcmfd

At lovance, cancer survivors are at the heart of everything we do. Today, we celebrate the strength, resilience, and determination of those who continue to inspire our mission to advance new possibilities for people living with cancer. #NationalCancerSurvivorsDay

What a week. From #ASCO26 to the Jefferies Healthcare Conference — and two exciting milestones in between: ✅ IND clearance for IOV-5001 ✅ Regulatory approval in Australia Proud to be advancing TIL cell therapy for patients who need it most. 🔗iovance.com

Today Fred Vogt, PhD, and Corleen Roche will participate in a fireside chat at the Jefferies Global Healthcare Conference at 1:25 p.m. ET. Register for the live webcast or replay here: ir.iovance.com/events/event-d…

AMTAGVI® (lifileucel) is now TGA-approved in Australia for advanced melanoma — a first-of-its-kind T cell therapy for a solid tumor cancer. Full press release here: ir.iovance.com/news-events/pr…

Visit us at Booth #13119! 🦈

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 ir.iovance.com/news-releases/…

lovance will present 2 posters today at #ASCO26 featuring ongoing research in cell therapy and solid tumors. Learn more below:

We are attending the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Stop by our booth to connect with our team and learn more about our ongoing work in cell therapy. #ASCO26

This #InternationalClinicalTrialsDay, we're celebrating the patients, clinicians, and researchers whose courage and commitment drive progress forward, and bring us closer to delivering innovative treatments with urgency. Read more: iovance.com/clinical-pipel…

Last week, we welcomed patients living with rare melanomas and their families to iCTC for #MelanomaAwarenessMonth. We are deeply grateful to them for sharing their stories.

Today Iovance reported first quarter 2026 financial results and corporate updates. We will host an audio webcast at 8:30 am ET today, join live or listen to the replay: ir.iovance.com/news-events/ev…

This Melanoma Monday, we recognize the urgency to advance progress for those impacted by melanoma. As Brian Gastman, M.D., shares, we remain committed to meaningful impact for patients and their families, because patients can’t wait.

On May 6, Arvind Natarajan, SVP Technical Development at Iovance, will join Friends of Cancer Research and Parker Institute for Cancer Immunotherapy to discuss how smarter, more flexible approaches can help move innovation forward: friendsofcancerresearch.org/event/unlockin…

This past weekend, Iovance proudly supported @AIMatMelanoma #StepsAgainstMelanoma in Birmingham, AL to celebrate the power of community and shared purpose to drive research forward.

Our team attended the inaugural Melanoma US Focus Meeting last week, reinforcing our commitment to patients with #AdvancedMelanoma. Discussions with partners and experts highlighted continued progress. We’re proud of Iovance’s role in advancing new possibilities for patients.